Show simple item record

dc.contributor.authorHowell, Anthony
dc.contributor.authorWardley, Andrew M
dc.date.accessioned2009-10-19T15:34:53Z
dc.date.available2009-10-19T15:34:53Z
dc.date.issued2005-07
dc.identifier.citationOverview of the impact of conventional systemic therapies on breast cancer. 2005, 12 Suppl 1:S9-S16 Endocr. Relat. Canceren
dc.identifier.issn1351-0088
dc.identifier.pmid16113103
dc.identifier.doi10.1677/erc.1.01003
dc.identifier.urihttp://hdl.handle.net/10541/84452
dc.description.abstractSurvival in women with breast cancer is improving in the western world, in part related to improved surgery, radiotherapy and adjuvant systemic therapy. Aromatase inhibitors are superior to tamoxifen in this clinical situation and several studies indicate that taxane-based chemotherapy is superior to non-taxane-based regimens. Herceptin is active alone in HER-2/neu +ve advanced breast cancer and four clinical trials are testing this agent in the adjuvant situation. It seems likely that herceptin will add to conventional therapies and thus will be the paradigm for the introduction of other biological therapies to improve cure rates.
dc.language.isoenen
dc.subjectBreast Canceren
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshAntineoplastic Agents
dc.subject.meshAromatase Inhibitors
dc.subject.meshBiological Therapy
dc.subject.meshBreast Neoplasms
dc.subject.meshFemale
dc.subject.meshHumans
dc.titleOverview of the impact of conventional systemic therapies on breast cancer.en
dc.typeArticleen
dc.contributor.departmentCRUK Department of Medical Oncology, University of Manchester, Christie Hospital, 550 Wilmslow Road, Manchester M20 4BX, UK. Anthony.Howell@christie-tr.nwest.nhs.uken
dc.identifier.journalEndocrine-Related Canceren
html.description.abstractSurvival in women with breast cancer is improving in the western world, in part related to improved surgery, radiotherapy and adjuvant systemic therapy. Aromatase inhibitors are superior to tamoxifen in this clinical situation and several studies indicate that taxane-based chemotherapy is superior to non-taxane-based regimens. Herceptin is active alone in HER-2/neu +ve advanced breast cancer and four clinical trials are testing this agent in the adjuvant situation. It seems likely that herceptin will add to conventional therapies and thus will be the paradigm for the introduction of other biological therapies to improve cure rates.


This item appears in the following Collection(s)

Show simple item record